Peginterferon-α-2a (40kD) Plus Ribavirin
- 46 Downloads
Pegylated interferon plus ribavirin is the standard first-line treatment in patients with chronic hepatitis C virus (HCV) mono-infection. Although the optimal anti-HCV regimen is not established in the more difficult-to-treat population with HIV-HCV co-infection, much of the data in this clinical setting have been derived from studies evaluating peginterferon-α-2a (40kD) [Pegasys®] plus ribavirin (Copegus®), most notably the APRICOT (AIDS Pegasys Ribavirin International Co-Infection Trial) and the ACTG (AIDS Clinical Trial Group) A5071 study. In particular, results of APRICOT — the largest study conducted to date with a pegylated interferon plus ribavirin in patients with HIV-HCV co-infection-indicate that a substantial proportion of patients will achieve sustained virological response (SVR) at week 72 when these drugs are administered for 48 weeks in an appropriate dosage regimen. In general, the tolerability profile of peginterferon-α-2a plus ribavirin in APRICOT was similar to that previously reported in patients with HCV mono-infection.
Interferons inhibit viral replication and/or function in infected cells via complex intracellular signalling processes induced by binding to specific cell surface receptors. The mechanism by which ribavirin exerts its antiviral effects against HCV is not known. Both peginterferon-α-2a and ribavirin have immunomodulatory effects, which may contribute to their activity.
Following subcutaneous administration of peginterferon-α-2a 180μg once weekly in patients with HCV infection, serum drug concentrations are sustained throughout the dosage interval, with peak concentrations approximately 1.5- to 2-fold higher than trough concentrations. Mean terminal elimination half-life (t1/2β) of peginterferon-α-2a is 80 hours compared with 5.1 hours for interferon-α-2a.
Ribavirin is rapidly and extensively absorbed following oral administration, although absolute bioavailability is only about 45–65%, probably as a result of first-pass metabolism. The drug has a very high volume of distribution (4500L) and long t1/2β (120–170 hours). Pharmacokinetic properties of ribavirin are similar in patients with HIV-HCV co-infection or HCV mono-infection.
Concomitant administration of peginterferon-α-2a and ribavirin in patients with HCV infection did not result in any pharmacokinetic interaction between these drugs. There is also no clinically significant interaction between peginterferon-α-2a and methadone.
A pharmacokinetic analysis in almost 50 patients with HIV-HCV co-infection receiving anti-HCV and antiretroviral therapy showed that ribavirin 800 mg/day does not affect the intracellular metabolism or plasma concentration-time profile of lamivudine (3TC), stavudine (d4T) and zidovudine (AZT). However, didanosine (dd1) is not recommended (and is generally strictly avoided in clinical practice) in patients receiving ribavirin, as fatalities and other serious adverse effects associated with didanosine have occurred as a result of increased formation of its active triphosphate anabolite.
Optimal regimens of subcutaneous pegylated interferon plus oral ribavirin achieve SVR rates, defined as an undetectable HCV RNA level at the end of a 24-week untreated follow-up period, in excess of 50–60% in previously untreated patients with HCV mono-infection. However, SVR rates are typically much lower in patients with HIV-HCV co-infection.
SVR was achieved in 40% of co-infected patients who received peginterferon-α-2a 180μg once weekly plus ribavirin 800 mg/day as first-line therapy for 48 weeks in the large (n = 860), multinational study known as APRICOT. This was significantly higher than the SVR rate of 20% with peginterferon-α-2a monotherapy, or the 12% SVR rate with interferon-α-2a plus ribavirin. The difference in SVR rates between the latter two regimens was also statistically significant, indicating that peginterferon-α-2a monotherapy is a viable treatment option in co-infected patients who are unable to take ribavirin. The pattern of SVR (peginterferon-α-2a plus ribavirin > peginterferon-α-2a > interferon-α-2a plus ribavirin) remained the same when patients were grouped according to HCV genotype (1 vs 2 or 3) or by HCV RNA levels (high vs low) at baseline.
First-line therapy with peginterferon-α-2a 180μg once weekly plus ribavirin also achieved a significantly higher SVR rate than interferon-α-2a plus ribavirin (27% vs 12%) in 133 co-infected patients randomised in the ACTG A5071 study. A dose-escalation schedule for ribavirin was used in the ACTG A5071 study, which may not have provided optimal therapy.
In general, the tolerability profile of peginterferon-α-2a plus ribavirin appears to be similar in patients with HIV-HCV co-infection to that in patients with HCV mono-infection. In addition, combination therapy with peginterferon-α-2a plus ribavirin was not associated with loss of HIV disease control in co-infected patients.
In the APRICOT study in patients with HIV-HCV co-infection, the most frequently reported adverse events with peginterferon-α-2a plus ribavirin (incidence ≥20%) were fatigue, pyrexia, headache, myalgia, nausea, diarrhoea, insomnia, asthenia and depression. Premature withdrawal from the trial because of adverse events or laboratory abnormalities occurred in 15% of patients in this treatment group, and 8% experienced a serious treatment-related adverse event. In general, there were few differences between treatment groups for most of these tolerability parameters. Although statistical analysis was not reported, clinically significant neutropenia was more likely to occur in treatment arms that included peginterferon-α-2a, and anaemia was more likely in treatment arms that included ribavirin.
In the ACTG A5071 trial, 12% of patients in both treatment groups discontinued therapy because of adverse events or laboratory abnormalities. The incidence of depression, influenza-like symptoms and laboratory abnormalities was also similar between treatment groups, although neutropenia of any grade was reported during the first 24 weeks of the trial in 55% of patients treated with peginterferon-α-2a plus ribavirin compared with 30% of those who received interferon-α-2a plus ribavirin (statistical analysis not reported).
KeywordsSustained Virological Response Sustained Virological Response Rate Fatigue Severity Scale Early Virological Response Apricot Study
- 2.Rockstroh J, Konopnicki D, Soriano V, et al. Hepatitis B and hepatitis C in the EuroSIDA cohort: prevalence and effect on mortality, AIDS, progression and response to HAART [abstract no. 799]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8–11; San FranciscoGoogle Scholar
- 19.Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40kD) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology. In pressGoogle Scholar
- 27.Roche. Pegasys® (peginterferon alfa-2a): complete product information [online]. Available from URL: http://www.rocheusa.com [Accessed 2004 Jun 4]
- 28.Xu Z-X, Hoffman J, Patel I, et al. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon α-2a (IFN α-2a) to healthy subjects [abstract no. 2157]. Hepatology 1998 Oct; 28 (4 Pt 2): 702ACrossRefGoogle Scholar
- 30.Roche. Copegus™ (ribavirin, USP) tablets: complete product information [online]. Available from URL: http://www.rocheusa.com [Accessed 2004 Jun 4]
- 32.Reddy KR, Fried MW, Shiffman ML, et al. The influence of cumulative exposure to combination peginterferon alfa-2a (40kD) (Pegasys) and ribavirin (Copegus) on sustained virological response (SVR) rates in patients with genotype 1 chronic hepatitis C [abstract no. 505]. J Hepatol 2004 Jan; 40 Suppl. 1: 149CrossRefGoogle Scholar
- 33.Torriani FJ, Rockstroh J, Rodriguez-Torres M, et al. Final week-72 results of the AIDS Pegasys ribavirin international co-infection trial (APRICOT): a randomized, partially blinded, multinational comparative trial of peginterferon alfa-2a (40kD) (Pegasys®) plus ribavirin (RBV) (Copegus®) vs interferon alfa-2a (IFN) [abstract no. 92]. J Hepatol 2004 Apr; 40 Suppl. 1: 33CrossRefGoogle Scholar
- 39.Gries J-M, Torriani FJ, Rodriguez-Torres M, et al. Ribavirin does not perturb the intracellular or plasma pharmacokinetics (PK) of nucleoside reverse transcriptase inhibitors (NRTI) in patients with HIV-HCV co-infection: final results of a randomized clinical study [poster no. 2.2]. 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004 Apr 1–3; RomeGoogle Scholar
- 42.Roche. Pegasys 180, SPC from the eMC [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2004 May 4]
- 43.Roche. Copegus 200mg, SPC from the eMC [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2004 May 4]
- 46.Sulkowski MS, Wright T, Rossi S, et al. Peginterferon alfa-2a (40KD) does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C on methadone maintenance therapy. Clin Pharmacol Ther. In pressGoogle Scholar
- 47.Sy S, Martin NE, Patel IH, et al. Drug interactions between PEG(40K)-IFNα-2a (Pegasys™) and cytochrome P450 (CYP450)-metabolized drugs are unlikely except for those metabolized by CYP1A2 [abstract no. 52.009]. 9th International Congress on Infectious Diseases; 2000 Apr 10–13: Buenos AiresGoogle Scholar
- 50.Ortega E, Martin A, Barros C, et al. An open-label, multicenter zstudy of the efficacy and safety of peginterferon alfa-2a (40kD) (Pegasys®), alone or in combination with ribavirin (Copegus®), in patients with HIV/HCV co-infection [abstract no. 497]. J Hepatol 2004 Apr; 40 Suppl. 1: 146. Plus poster presented at the 39th Annual Meeting of the European Association for the Study of the Liver; 2004 Apr 14–18; BerlinCrossRefGoogle Scholar
- 51.Hernández-Quero J, Granados R, Pérez-Guzmán E, et al. Peginterferon alfa-2a (40kD) (Pegasys®) and ribavirin (Copegus®) in patients with HIV/HCV coinfection: interim results of a randomized, multicenter study from Spain [abstract no. 987]. Hepatology 2003 Oct; 38 (4 Suppl. 1): 631 A. Plus poster presented at the 54th Annual Meeting of the American Association for the Study of Liver Diseases; 2003 Oct 24–28; BostonGoogle Scholar
- 52.Rodriguez-Torres M, Rodriguez-Orengo J. Efficacy of pegIFN-alfa 2A (Pegasys) vs Pegasys and RBV for HIV/HCV coinfected patients that are nonresponders to previous IFN therapy [abstract no. 343]. Hepatology 2003 Oct; 38 (4 Suppl. 1): 325. Plus poster presented at the 54th Annual Meeting of the American Association for the Study of Liver Diseases; 2003 Oct 24–28; BostonCrossRefGoogle Scholar
- 53.Rodriguez-Torres M, Dieterich DT, Lissen E, et al. Predictability of sustained virological response (SVR) at week 4 in HIV-HCV co-infected patients treated with peginterferon alfa-2a (40kD) (Pegasys®) + ribavirin (Copegus®) in the AIDS Pegasys Ribavirin International Co-Infection Trial (APRICOT) [abstract no. H-1751 plus oral presentation]. 44th Inter-science Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DCGoogle Scholar
- 54.Dieterich DT, Rodriguez-Torres M, Rockstroh JK, et al. HIV-HCV co-infected patients achieving a sustained virological response (SVR) with peginterferon alfa-2a (40kD) (Pegasys®) plus ribavirin (Copegus®) have improved health-related quality of life (HRQL) [abstract H-1750 plus oral presentation]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DCGoogle Scholar
- 55.Lissen E, Clumeck N, Sola R, et al. Histological response to peginterferon alfa-2a (40kD) (Pegasys®) plus ribavirin (Copegus®) in patients with HIV-HCV co-infection: results of the AIDS Pegasys Ribavirin International Co-Infection Trial (APRICOT) [abstract no. 174]. Hepatology 2004; 40 Suppl. 1: 241AGoogle Scholar
- 57.Bräu N, Torriani FJ, Rodriguez-Torres M, et al. Safety of peginterferon alfa-2a (Pegasys) 180 mcg weekly plus ribavirin (RBV) 800 mg daily in HIV/HCV coinfection compared to HCV monoinfection [abstract no MoPeB3311 plus poster]. XV International AIDS Conference; 2004 Jul 11–16; BangkokGoogle Scholar
- 61.Sarmento C, Horta A, Coelho H, et al. Moderate dose of peginterferon alfa-2b in combination with ribavirin in the treatment of HCV patients with or without HIV [abstract no. MoPeB3322]. XV International AIDS Conference; 2004 Jul 11–16; BangkokGoogle Scholar
- 64.Perronne C, Bani-Sadr F, Carrat F, et al. Final results of ANRS HCO2-RIBAVIC: a randomized controlled trial of pegylated-interferon alfa-2b plus ribavirin vs interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients [abstract no. MoPeB3295 plus poster]. XV International AIDS Conference; 2004 Jul 11–16; BangkokGoogle Scholar